Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Tak Mak

Lewis Cantley

Craig Thompson

Shin-San Michael Su

Agios Pharmaceuticals, Inc.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBV Technologies S.A.

Eilean Therapeutics is a small molecule oncology drug discovery company that develops pan-variant therapies for hematologic malignancies targeting major drivers of cancer resistance.

Metric
Company Name	Agios Pharmaceuticals, Inc.	DBV Technologies S.A.	Eilean Therapeutics
Symbol	AGIO	DBV
MSH ID	COM:AGIOS	COM:DBV-TECHNOLOGIES	COM:EILEANTHER
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	FR	US
Stage
Employee Count	383	105
Website	agios.com	dbv-technologies.com	eileanther.com
LinkedIn		dbv-technologies
Founders

Metric
Market Cap	2.47B	77.97M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	26.82M
Revenue (LTM)
Revenue (NTM)
Gross Profit	17.32M
EBITDA	-384.86M
Operating Income	-391.49M
Net Income	-352.09M
EPS	-6.33
Diluted EPS	-6.33
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.84
Operating Profit Margin	-12.94
EBITDA Margin	-14.35
Net Profit Margin	-11.66
Return on Equity	-0.37
Return on Assets	-0.37
Return on Capital Employed	-0.45

COM:AGIOS

Agios Pharmaceuticals, Inc.

Last Close

55.54

22/11 21:00

Market Cap

2.47B

Beta: -

Volume Today

419.15K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-23.82
P/B Ratio	1.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	96.00
EV Multiple	-4.30

Metric
Days Sales Outstanding	40.78
Days Payables Outstanding	1.64K
Days Inventory Outstanding	1.63K
Operating Cycle	1.66K
Cash Conversion Cycle	830.26
Asset Turnover	0.04

Metric
Operating Cash Flow	-296.06M
Free Cash Flow	-297.06M
Cash Flow to Debt	-4.11
Operating Cash Flow/Sales	-9.79
Free Cash Flow Yield	-0.23

Metric
Cash & Equivalents	88.20M
Accounts Receivable	-604K
Inventory	19.08M
Goodwill
Debt to Capitalization	0.09
Debt to Assets	0.07
Current Ratio	13.73
Quick Ratio	12.39

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	2.21
R&D to Revenue	13.47
SG&A to Revenue